1. U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Multaq (dronedarone) briefing document. March18, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM134981.pdf (accessed 2010 Feb 1).
2. U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Kynapid (vernakalant hydrochloride injection) briefing materials. December11, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1-01-astellas-backgrounder.pdf (accessed 2010 Feb 1).
3. The arrhythmias;Sanoski,2008
4. Vernakalant in the management of atrial fibrillation;Cheng;Ann Pharmacother,2008